Form4insider filings, from the source

SEC Form 4 · accession 0001209191-15-038608

CELGENE CORP /DE/ · CELG

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Perry A Karsen
Officer — see remarks
Period of report
Apr 30, 2015
Accepted (ET)
May 4, 2015 · 7:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Apr 30, 2015M11,200$0.00A85,330D
Common StockApr 30, 2015F5,807$108.06D79,523D
Common Stockholding———1,639I401(k) Plan
Common Stockholding———2,000IIRA Account

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Restricted Stock UnitF2,F1—Apr 30, 2015M11,200D——Common Stock11,2000D
Stock Option (right to buy)F4,F3$109.90May 4, 2015A12,125A—May 4, 2025Common Stock12,12512,125D

Explanation of responses

Remarks

Chief Executive Officer of Celgene Cellular Therapeutics